Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Cost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Entera Bio (ENTX) Cost of Revenue (2019 - 2025)

Entera Bio has reported Cost of Revenue over the past 6 years, most recently at $42000.0 for Q1 2025.

  • For the quarter ending Q1 2025, Cost of Revenue changed N/A year-over-year to $42000.0, compared with a TTM value of $42000.0 through Dec 2025, down 75.58%, and an annual FY2025 reading of $42000.0, down 75.58% over the prior year.
  • Cost of Revenue came in at $42000.0 for Q1 2025, down from $82000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $136000.0 in Q4 2021 to a low of $6000.0 in Q3 2022.
  • Median Cost of Revenue over the past 4 years was $51000.0 (2022), compared with a mean of $57333.3.
  • The sharpest move saw Cost of Revenue surged 219.35% in 2021, then crashed 94.12% in 2022.
  • Over 4 years, Cost of Revenue stood at $136000.0 in 2021, then crashed by 94.12% to $8000.0 in 2022, then soared by 925.0% to $82000.0 in 2024, then plummeted by 48.78% to $42000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Cost of Revenue are $42000.0 (Q1 2025), $82000.0 (Q4 2024), and $42000.0 (Q3 2024).